Logo for Aerovate Therapeutics Inc

Aerovate Therapeutics Investor Relations Material

Latest events

Logo for Aerovate Therapeutics

Q2 2024

12 Aug, 2024
Logo for Aerovate Therapeutics

Q1 2024

13 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Aerovate Therapeutics Inc

Access all reports
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases. The company's lead product candidate is AV-101, a dry powder inhaled formulation of imatinib, designed to treat pulmonary arterial hypertension (PAH). This formulation aims to deliver the drug directly to the lungs, targeting the underlying disease mechanisms while minimizing systemic side effects. Aerovate Therapeutics is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.